Nuvalent, Inc.

NASDAQ: NUVL · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0001861560Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 65DQ —GM —SS 62

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, market scale · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$425.4M

Employees

234

as of 2026-08-06

Market cap

$9.1B

as of 2026-08-06

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$425.4M-$425.4M2025

Operating income-$414.3M-$414.3M2025

Total assets$1.4B$1.4B2025

Liabilities$164.4M$164.4M2025

Equity$1.2B$1.2B2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Nuvalent, Inc.’s financial profile?

Nuvalent, Inc. earned -$425.4M in FY2025 net income.

Peers · Healthcare

NexImmune, Inc.——ContraFect Corp.——Heart Tronics, Inc.——Apogee Therapeutics, Inc.——Immunovant, Inc.——Vaxcyte, Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOJames R. Porter

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: NUVL

Employees234

IPO date2021-07-29

Latest filings

8-K2026-07-15 8-K2026-06-18 8-K2026-06-09 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-28 8-K2026-04-07 8-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.